156772-60-0

Basic information

• Product Name: 2,5-DIBROMO-3-FLUOROPYRIDINE
• Synonyms: 2,5-DIBROMO-3-FLUOROPYRIDINE
• CAS NO: 156772-60-0
• Molecular Formula: C₅H₂Br₂FN
• Molecular Weight: 254.88
• Product Categories: Pyridine;Halides;Heterocycles;Pyridines;Boronic Acid;pyridine series
• Mol File: 156772-60-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 215.9 °C at 760 mmHg
• Flash Point: 84.4 °C
• Appearance: White/Solid
• Density: 2.137 g/cm³
• Vapor Pressure: 0.212mmHg at 25°C
• Refractive Index: 1.58
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -3.99±0.20(Predicted)
• CAS DataBase Reference: 2,5-DIBROMO-3-FLUOROPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-DIBROMO-3-FLUOROPYRIDINE(156772-60-0)
• EPA Substance Registry System: 2,5-DIBROMO-3-FLUOROPYRIDINE(156772-60-0)

Safety Data

• RIDADR: UN2811
• HazardClass: 6.1
• Hazardous Substances Data: 156772-60-0(Hazardous Substances Data)

Usage

Uses

2,5-Dibromo-3-fluoropyridine can be used as PRC2 inhibitors to treat cancer.

InChI:InChI=1/C5H2Br2FN/c6-3-1-4(8)5(7)9-2-3/h1-2H

Upstream product

• 90902-84-4 2,5-dibromopyridin-3-ylamine 

Downstream Products

• 156772-62-2 5-bromo-3-fluoro-2-(4-octyloxyphenyl)pyridine 
• 1160936-52-6 1-(5-bromo-3-fluoropyridin-2-yl)ethan-1-one 
• 1162674-74-9 5-bromo-3-fluoro-2-methylpyridine 

Relevant articles and documents

Application of 1,1-ADEQUATE, HMBC, and Density Functional Theory to Determine Regioselectivity in the Halogenation of Pyridine N-Oxides

The 1,1-ADEQUATE spectrum clearly shows specific two-bond proton to carbon correlations to unequivocally distinguish the major and minor regioisomers of ortho-halogenated pyridines and to aid in assignment of the corresponding proton and carbon chemical shifts. M06-2X/6-31+G(d,p) free energies of the regioisomeric intermediates arising from deprotonation correctly predict the experimentally observed preference and thus can be used to tune the substituent pattern to yield a desired regiochemical outcome.

NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS

The invention relates to individual alkyne compounds with an antagonistic action against the MCH-receptor. Said compounds are suitable for producing medicaments for the treatment of metabolic disorders and/or eating disorders, in particular adiposity and diabetes.

NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS CONTAINING SAID COMPOUNDS

The invention relates to alkyne compounds of general formula (I), in which the groups and radicals A, B, W, X, Y, Z, R1 and R2 are defined as cited in claim 1. The invention also relates to medicaments containing at least one inventive alkyne. As a result of the antagonistic action against the MCH-receptor, the inventive medicaments are suitable for treating metabolic disorders and/or eating disorders, in particular adiposity and diabetes.